No evidence for enhanced disease with polyclonal SARS-CoV-2 antibody in the ferret model
ABSTRACT Since SARS-CoV-2 emerged in late 2019, it spread from China to the rest of the world. An initial concern was the potential for vaccine- or antibody-enhanced disease (AED) as had been reported with other coronaviruses. To evaluate this, we first developed a ferret model by exposing ferrets to SARS-CoV-2 by either mucosal inoculation (intranasal/oral) or inhalation using a small particle aerosol. Mucosal inoculation caused a mild fever and weight loss that resolved quickly; inoculation via either route resulted in virus shedding detected in the nares, throat, and rectum for 7-10 days post-infection. To evaluate the potential for AED, we then inoculated groups of ferrets intravenously with 0.1, 0.5, or 1 mg/kg doses of a human polyclonal anti-SARS-CoV-2 IgG from hyper-immunized transchromosomic bovines (SAB-185). Twelve hours later, ferrets were challenged by mucosal inoculation with SARS-CoV-2. We found no significant differences in fever, weight loss, or viral shedding after infection between the three antibody groups or the controls. Signs of pathology in the lungs were noted in infected ferrets but no differences were found between control and antibody groups. The results of this study indicate that healthy, young adult ferrets of both sexes are a suitable model of mild COVID-19 and that low doses of specific IgG in SAB-185 are unlikely to enhance the disease caused by SARS-CoV-2..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 24. Aug. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reed, Douglas S. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.08.19.553970 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI040587061 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI040587061 | ||
| 003 | DE-627 | ||
| 005 | 20231205144348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230822s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.08.19.553970 |2 doi | |
| 035 | |a (DE-627)XBI040587061 | ||
| 035 | |a (biorXiv)10.1101/2023.08.19.553970 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reed, Douglas S. |e verfasserin |0 (orcid)0000-0003-0076-9023 |4 aut | |
| 245 | 1 | 0 | |a No evidence for enhanced disease with polyclonal SARS-CoV-2 antibody in the ferret model |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Since SARS-CoV-2 emerged in late 2019, it spread from China to the rest of the world. An initial concern was the potential for vaccine- or antibody-enhanced disease (AED) as had been reported with other coronaviruses. To evaluate this, we first developed a ferret model by exposing ferrets to SARS-CoV-2 by either mucosal inoculation (intranasal/oral) or inhalation using a small particle aerosol. Mucosal inoculation caused a mild fever and weight loss that resolved quickly; inoculation via either route resulted in virus shedding detected in the nares, throat, and rectum for 7-10 days post-infection. To evaluate the potential for AED, we then inoculated groups of ferrets intravenously with 0.1, 0.5, or 1 mg/kg doses of a human polyclonal anti-SARS-CoV-2 IgG from hyper-immunized transchromosomic bovines (SAB-185). Twelve hours later, ferrets were challenged by mucosal inoculation with SARS-CoV-2. We found no significant differences in fever, weight loss, or viral shedding after infection between the three antibody groups or the controls. Signs of pathology in the lungs were noted in infected ferrets but no differences were found between control and antibody groups. The results of this study indicate that healthy, young adult ferrets of both sexes are a suitable model of mild COVID-19 and that low doses of specific IgG in SAB-185 are unlikely to enhance the disease caused by SARS-CoV-2. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a McElroy, Anita K. |4 aut | |
| 700 | 1 | |a Barbeau, Dominique J. |0 (orcid)0000-0001-6493-5022 |4 aut | |
| 700 | 1 | |a McMillen, Cynthia M. |0 (orcid)0000-0001-9211-7908 |4 aut | |
| 700 | 1 | |a Tilston-Lunel, Natasha L. |0 (orcid)0000-0002-5290-9350 |4 aut | |
| 700 | 1 | |a Nambulli, Shamkumar |4 aut | |
| 700 | 1 | |a Cottle, Emily |4 aut | |
| 700 | 1 | |a Gilliland, Theron C. |4 aut | |
| 700 | 1 | |a Rannulu, Hasala |4 aut | |
| 700 | 1 | |a Lundy, Jeneveve |4 aut | |
| 700 | 1 | |a Olsen, Emily L. |4 aut | |
| 700 | 1 | |a O’Malley, Katherine J. |4 aut | |
| 700 | 1 | |a Xia, Mengying |4 aut | |
| 700 | 1 | |a Hartman, Amy L. |0 (orcid)0000-0002-0857-2973 |4 aut | |
| 700 | 1 | |a Luke, Thomas C |4 aut | |
| 700 | 1 | |a Egland, Kristi |4 aut | |
| 700 | 1 | |a Bausch, Christoph |4 aut | |
| 700 | 1 | |a Wu, Hua |4 aut | |
| 700 | 1 | |a Sullivan, Eddie J. |0 (orcid)0000-0001-7468-2006 |4 aut | |
| 700 | 1 | |a Klimstra, William B. |4 aut | |
| 700 | 1 | |a Duprex, W. Paul |0 (orcid)0000-0003-1716-6376 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 24. Aug. |
| 773 | 1 | 8 | |g year:2023 |g day:24 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.08.19.553970 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 24 |c 08 | ||